Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/20/2003US6565827 Anticarcinogenic agents
05/20/2003CA2322944C Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
05/20/2003CA2262001C Mhc binding peptide oligomers and methods of use
05/20/2003CA2215534C Stable protein: phospholipid compositions and methods
05/20/2003CA2131551C Conjugates formed from heat shock proteins and oligo- or polysaccharides
05/20/2003CA2110693C Amino acid derivative anticonvulsant
05/20/2003CA2102302C Recombinant defective adenoviruses expressing cytokines for an antitumoral treatment
05/20/2003CA2099994C Phenyl amidines derivatives useful as platelet aggregation inhibitors
05/15/2003WO2003041128A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
05/15/2003WO2003040693A2 Peptides that home to tumor lymphatic vasculature and methods of using same
05/15/2003WO2003040691A2 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
05/15/2003WO2003040686A2 Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
05/15/2003WO2003040399A2 Therapeutic methods for nucleic acid delivery vehicles
05/15/2003WO2003040375A1 COMPOSITIONS AND PROCESSES USING siRNA, AMPHIPATHIC COMPOUNDS AND POLYCATIONS
05/15/2003WO2003040371A1 Novel g protein-coupled receptor protein and dna thereof
05/15/2003WO2003040370A1 Weed controller metabolism proteins, genes thereof and use of the same
05/15/2003WO2003040369A2 Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
05/15/2003WO2003040368A2 Pharmaceutical compositions of marine sponge microciona prolifera
05/15/2003WO2003040366A2 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003WO2003040365A2 Pna-conjugate or pna-conjugate mixture for treating diseases related to the human papillomavirus
05/15/2003WO2003040346A2 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
05/15/2003WO2003040345A2 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003WO2003040339A2 Antisense modulation of purinoreceptor p2x¿3?
05/15/2003WO2003040337A2 Polyamide modulators of cox2 transcription
05/15/2003WO2003040336A2 Stem and progenitor cell capture for tissue regeneration
05/15/2003WO2003040333A2 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
05/15/2003WO2003040330A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040328A2 Antisense modulation of thyroid hormone receptor interactor 6 expression
05/15/2003WO2003040327A2 Novel human proteins, polynucleotides encoding them and methods of using the same
05/15/2003WO2003040325A2 Novel proteins and nucleic acids encoding same
05/15/2003WO2003040321A2 Antisense modulation of eif2c1 expression
05/15/2003WO2003040320A2 Antisense modulation of human collapsin response mediator protein 2 expression
05/15/2003WO2003040317A2 Lung cancer therapeutics and diagnostics
05/15/2003WO2003040313A2 Il-21 antagonists
05/15/2003WO2003040311A2 Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
05/15/2003WO2003040310A2 Novel epidermal growth factor protein and gene, and methods of use therefor
05/15/2003WO2003040309A2 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
05/15/2003WO2003040307A2 Heteromultimeric tnf ligand family members
05/15/2003WO2003040304A2 Method of proliferation in neurogenic regions
05/15/2003WO2003040301A2 Cell cycle progression proteins
05/15/2003WO2003040296A2 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003040294A2 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs
05/15/2003WO2003040187A1 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
05/15/2003WO2003040184A1 Novel protein and dna thereof
05/15/2003WO2003040183A2 Compounds for the diagnosis/prevention/treatment of alzheimer's disease
05/15/2003WO2003040182A1 Antisense oligonucleotides modulating bcl-2 expression
05/15/2003WO2003040178A1 Method for identifying or screening anti-viral agents
05/15/2003WO2003040176A2 Peptide decoys for the preparation of medicaments that are intended for the prevention or treatment of autoimmune pathologies or problems linked to the appearance of antibodies directed against exogenous proteins
05/15/2003WO2003040174A2 Substituted amino ketone compounds
05/15/2003WO2003040173A1 ANTAGONISTS FOR α4-INTEGRINS
05/15/2003WO2003040172A2 Methods and reagents for peptide-bir interaction screens
05/15/2003WO2003040167A2 Peptides which deliver antisense oligonucleotides and downregulate protein expression in cells
05/15/2003WO2003040164A2 Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
05/15/2003WO2003040161A2 Antisense modulation of activating transcription factor 3 expression
05/15/2003WO2003040137A1 Dimeric compounds and their use as anti-viral agents
05/15/2003WO2003039677A2 Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
05/15/2003WO2003039600A1 Selective treatment of il-13 expressing tumors
05/15/2003WO2003039590A1 Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
05/15/2003WO2003039589A1 Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides
05/15/2003WO2003039588A1 Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors
05/15/2003WO2003039587A1 Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
05/15/2003WO2003039586A1 Pharmaceutical composition comprising factor vii polypeptides and thrombomodulin polypeptides
05/15/2003WO2003039585A1 Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
05/15/2003WO2003039584A1 Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides
05/15/2003WO2003039583A1 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
05/15/2003WO2003039582A1 Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
05/15/2003WO2003039581A1 Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
05/15/2003WO2003039580A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003WO2003039579A1 Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
05/15/2003WO2003039578A1 Treatment of congestive heart failure
05/15/2003WO2003039577A1 Remedies for dry eye and diseases associated with dry eye
05/15/2003WO2003039576A1 Psp-94: use for treatment of hypercalcemia and bone metastasis
05/15/2003WO2003039575A2 Use of reelin, gas6, and protein s in the treatment of neural disorders
05/15/2003WO2003039574A1 Endophilin homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003039573A1 TARGETING THE REVERSE MODE OF THE Na+/Ca2+ EXCHANGER FOR THE TREATMENT OF OPTIC NEUROPATHY ASSOCIATED WITH GLAUCOMA AND ISCHEMIC OPTIC NEUROPATHY
05/15/2003WO2003039571A1 Improved use of antitumoral compound in cancer therapy
05/15/2003WO2003039567A1 Anticancer compositions
05/15/2003WO2003039566A2 Methods of treatment in situ in the lungs of mammals
05/15/2003WO2003039564A1 Selective targeting of apoptotic cells
05/15/2003WO2003039555A2 Agents for treating lesions of the nervous system
05/15/2003WO2003039534A1 Compositions and methods for treating osteoporosis
05/15/2003WO2003039525A1 Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
05/15/2003WO2003039511A1 New use of ethoxylated phytosterols and phytostanols
05/15/2003WO2003039509A1 Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion
05/15/2003WO2003039491A2 Novel isoforms of vascular endothelial cell growth inhibitor
05/15/2003WO2003039487A2 Cyclo(prolyl-glycine) and methods of use to treat neural disorders
05/15/2003WO2003039476A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
05/15/2003WO2003039475A2 Methods of identifying and using modulators of fractalkine receptor
05/15/2003WO2003039474A2 Method and composition for the modulation of angiogenesis
05/15/2003WO2003039466A2 Method of treating estrogen responsive breast cancer
05/15/2003WO2003039462A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003WO2003039458A2 TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
05/15/2003WO2003039455A2 Methods of treating endometreosis
05/15/2003WO2003039454A2 Beta-secretase inhibitors and methods of use
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039444A2 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
05/15/2003WO2003039442A2 Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition
05/15/2003WO2003039441A2 Unc-13 in the modulation of neurotransmission and secretion events
05/15/2003WO2003039438A2 Pna-conjugates for treating chronic myeloid leukaemia (cml)
1 ... 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 ... 3163